◎钱佳滢 记者 仲茜 1月4日，苏州召开苏州市新型工业化推进会议暨"AI+制造"创新发展大会，吹响新一年以制造业为抓 手，推动实体经济高质量发展的冲锋号。 大会对《苏州市推进新型工业化2026年行动方案》做出解读，明确了2026年苏州推进新型工业化的路线 图与施工图。2026年，苏州将以争创国家新型工业化示范区为主线，坚持智能化、绿色化、融合化方 向，实施新型工业化"八大工程"28项行动，推动规上工业总产值突破5万亿元。 在深化"1030"产业体系建设方面：苏州将推进高端装备、电子信息、新材料、新能源等新兴支柱产业壮 大，冶金、化工、轻工、纺织等传统优势产业焕新，低空经济、具身智能、细胞与基因技术、氢能与核 聚变等未来产业加快培育；推动纳米新材料、生物医药及高端医疗器械、高端科技仪器等六个国家先进 制造业集群迈向世界级。 为促进企业与高校、科研院所协同开展技术攻关，272项苏州市制造业"1030"产业关键核心技术攻关方 向在大会上发布，涵盖新能源、新一代信息技术、生物医药及大健康、高端装备、新能源汽车等十大产 业集群，为技术创新与产业升级指明方向。 大会上，"AI+制造"八大行动正式发布，提出动态培育150个 ...

交易信息汇总资金流向 截至2025年12月31日收盘，同益中(688722)报收于19.55元，下跌2.54%，换手率3.63%，成交量8.14万 手，成交额1.59亿元。 当日关注点 同益中关于获得政府补助的公告 北京同益中新材料科技股份有限公司近日收到山东省新泰市经济开发区管理委员会批复，同意拨付电费 价差补贴款1,542万元，属于与收益相关的政府补助，占公司2024年度经审计归母净利润的11.84%。截 至公告日，已到账500万元。公司预计该补助将增加2025年度归母净利润500万元，具体会计处理以审计 结果为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：12月31日主力资金净流出2938.9万元，占总成交额18.46%。 来自公司公告汇总：同益中获政府补助1,542万元，其中500万元已到账，预计增加2025年度归母 净利润500万元。 12月31日主力资金净流出2938.9万元，占总成交额18.46%；游资资金净流入942.92万元，占总成交额 5.92%；散户资金净流入1995.98万元，占总成 ...

（来源：衢州日报） 转自：衢州日报 记者 王继红 通讯员 余荣贵 【关键词】 1000亿元 【新闻现场】 "十四五"期间，我市"六大产业"发展风生水起，其中新材料产业更是在2025年率先突破千亿元产值大 关。巨化集团、衢州华友、中天氟硅、拓烯光学、奥首材料等新老企业共同发力下，实现了这一里程碑 式的跨越。 1月4日，记者走进巨化集团下属企业、浙江歌瑞新材料有限公司（以下简称"歌瑞公司"），跟着工作人 员看产品、探车间、观产线、听介绍，一个多小时里，目不暇接、脚步不停，"专精特新"四个印象扑面 而来…… 新，是新材料之灵魂，一代材料支撑起一代产业，数智化则是创新之内核。 专，新材料是个10万亿元级的大市场，产品种类多、要求高，在歌瑞公司同样体现在数量众多的产品 中。在制品异形件生产线上，员工罗创阳在加工一批产品。这位2001年出生、来自河南的小伙子熟练地 操作着机床，不到4秒时间，一个产品便下线。小罗的上游和下游工序，有着数十种不同的产品，每一 类产品都有各自的要求与不同的加工设备。 精，歌瑞公司产品有白色的、黑色的，有管件、航材、油封等，机床有绿色的、黄色的，就是机器人也 有橙色、黄色两种。在歌瑞公司，每一种 ...

据公告，本次激励计划采用限制性股票形式，标的股票来源为公司定向发行的A股普通股。其中，首次 授予2165.00万股，占拟授予总数的99.59%，预留9.00万股占比0.41%。首次授予价格确定为7.99元/股， 覆盖313名激励对象，涵盖董事、高级管理人员及核心管理、技术（业务）人员。 业绩考核方面，该计划设定了明确的长期增长目标。以2024年净利润为基数，2026年至2028年净利润复 合增长率均不低于13%，且不低于同行业均值或对标企业75分位值；净资产收益率逐年提升，分别不低 于7.00%、7.40%、7.50%，同样需达到行业75分位值水平；同时三年年末资产负债率均需控制在67%以 内。 12月31日晚间，株洲时代新材（600458）料科技股份有限公司（以下简称"时代新材"）公告，拟授予 2174.00万股限制性股票绑定核心骨干，约占本激励计划草案公布日公司股本总额的2.33%。此前，时代 新材公告，2023年度定增募投"创新中心及智能制造基地项目"顺利结项。上述举措叠加，既彰显时代新 材调动核心团队积极性的决心，也为"十五五"期间高质量发展筑牢基础。 "当前全球产业链正处于重构加速的关键阶段，新材料 ...

Group 1 - Beijing plans to support the construction of pilot test platforms for key industries such as artificial intelligence, healthcare, green low-carbon technologies, robotics, and smart manufacturing, with subsidies of up to 100 million RMB, covering 35% of total investment for new projects [1][2] - The goal is to establish 10 national-level manufacturing pilot test platforms and 50 municipal-level platforms by 2030, forming a pilot test system that meets the requirements of the capital's modern industrial system [1] - The measures encourage collaboration among leading enterprises in the industry chain to co-build pilot production lines, support the establishment of comprehensive pilot public service institutions, and enhance the digital and green capabilities of existing platforms [1][2] Group 2 - The measures also emphasize the collaborative construction of pilot transformation bases in key areas such as hydrogen energy, biomedicine, cybersecurity, industrial internet, high-end equipment, new energy, and intelligent connected vehicles within the Beijing-Tianjin-Hebei region [2] - A service platform for matching supply and demand in pilot testing services will be established, along with a focus on strengthening financial investment in pilot services [2]

近年来，中国证监会在融资端改革持续发力，接续推出"科创十六条""科创板八条"等举措，设立科创板 科创成长层，启用创业板第三套上市标准。江苏证监局在中国证监会和江苏省委、省政府的坚强领导 下，立足江苏产业实际，聚焦"五个服务"，强化政策宣导，加大科技创新企业培育力度，充分发挥资本 市场枢纽功能，有力支持优质企业对接资本市场实现高质量发展。 在顶层制度设计与一线监管服务的共同滋养下，一批江苏企业乘势而上，成为资本市场包容性与吸引力 的生动注脚。2025年，江苏新增境内上市公司29家，占比全国1/4，以资本市场的蓬勃活力，为经济大 省"挑大梁"提供了坚实支撑，助力江苏"在推进中国式现代化中走在前、做示范"。 畅通多元融资渠道，激活科创"一池春水" 近年来，多层次市场体系对科技创新的覆盖面有效拓展，各板块各具特色、错位发展，为处于不同阶段 的科技企业铺设了多元包容的上市路径。 29家首发企业均为科技创新企业，多个"首家""首例"在苏落地，清晰勾勒出资本要素向创新领域密集汇 聚的"江苏路线图谱"，成为包容性制度转化为发展动能的最好证明。 全国首家适用新三板"绿色通道+直联审核"机制的创新层企业，创造了"当天申报、当天受 ...

Core Viewpoint - The article highlights the ongoing reforms in China's capital market, particularly in Jiangsu province, aimed at enhancing support for technology innovation enterprises and facilitating their access to financing through various initiatives and policies [1][2][8]. Group 1: Financing Reforms and Initiatives - The China Securities Regulatory Commission (CSRC) has introduced multiple measures such as the "16 Articles on Science and Technology Innovation" and the "8 Articles on the Science and Technology Innovation Board" to improve financing channels for innovative companies [1]. - Jiangsu's capital market has seen a significant increase in the number of listed companies, with 29 new domestic listings expected by 2025, accounting for 25% of the national total [1]. - A record was set for the speed of financing for small and medium-sized technology innovation enterprises, with a company completing the entire process from application to approval in just 34 trading days [2]. Group 2: Industry Development and Market Integration - Jiangsu's listed companies now cover a comprehensive "1650" industrial system, indicating a deep integration between the capital market and local industry [3]. - The semiconductor industry in Jiangsu is set to welcome two new listed companies by 2025, with one already marking a milestone as the first new stock on the Science and Technology Innovation Board this year [3]. - The biopharmaceutical sector is actively engaging with the capital market, with several companies expressing intentions to return to A-shares for development [3]. Group 3: New Industry Opportunities - The focus on future industries, such as artificial intelligence and commercial aerospace, is emphasized as part of Jiangsu's strategic development, with reforms extending support to these sectors [4][5]. - Several companies are planning to apply for the fifth set of standards on the Science and Technology Innovation Board, which caters to hard-tech enterprises that may not yet be profitable but represent future technological directions [5]. Group 4: Internationalization and Market Expansion - Jiangsu has seen an increase in companies successfully obtaining listings in Hong Kong, with the total number of A+H listed companies reaching 9, indicating a growing international presence [6]. - A biopharmaceutical company raised approximately HKD 9.89 billion in its IPO on the Hong Kong Stock Exchange, marking the largest financing scale in the Hong Kong medical sector since 2020 [6]. Group 5: Quality and Governance in Listings - The Jiangsu Securities Regulatory Bureau emphasizes the importance of balancing development and safety, focusing on high-quality listings through proactive regulatory support [7]. - Over 20 specialized policy seminars and case analysis meetings have been conducted to guide companies in establishing a correct understanding of the listing process and governance [7]. - The regulatory body aims to enhance the quality of listed companies by ensuring that capital flows towards enterprises that represent technological and industrial innovation [7]. Group 6: Future Outlook - The Jiangsu Securities Regulatory Bureau plans to enhance the inclusivity and adaptability of capital market systems to support technological self-reliance and cultivate new productive forces [8]. - The bureau will implement measures to ensure that supportive policies effectively reach enterprises, translating reform policies into development momentum [8].

Group 1 - The core point of the article is the establishment of Liaoning Anshidi Material Technology Co., Ltd., which is involved in advanced material technology and manufacturing [1] - The company has a registered capital of 20 million yuan [1] - The business scope includes research and development of new material technology, manufacturing of forgings and powder metallurgy products, additive manufacturing, and sales of additive manufacturing equipment [1] Group 2 - The company is jointly owned by Anshan Iron and Steel Group Co., Ltd. and Ansteel Group Beijing Research Institute Co., Ltd. [1]

近日，2025年广西科技创新"首字号"重大成果发布，20项填补国内空白、突破国际垄断的技术成果 集中亮相，标志着广西高水平科技自立自强建设取得新突破。 自治区科技厅相关负责人介绍，2025年，广西聚焦先进新材料、高端装备制造、新能源及储能、现 代特色农林等"7+2"重点领域，深入实施新一轮科技"尖锋"行动。着力优化重大科技任务生成与组织机 制，依托中国工程科技发展战略广西研究院等智库力量，构建覆盖"战略咨询—产业图谱—重大专项— 创新成果—产业赋能"的全链条设计体系，推动科研、企业、产业链、供应链等资源要素一体化配置。 运用"一图谱两清单"方法精准凝练产业关键技术攻关任务，组织实施关键金属新材料等10个产业链创新 重大科技专项，组织实施重大项目82项，突破重大技术102项。 亮眼成果背后是广西创新生态的持续优化。近年来，广西围绕产业创新发展加强高质量科技供给， 实施产业需求牵引的"七个一"行动，即围绕一个重点产业，建设一批高峰高原学科专业群，打造一批高 能级科技创新平合，实施一批产学研联合攻关项目，转化一批科技创新成果，支撑一批科技型企业，引 育一批骨干创新人才，大力推动科技创新和产业创新深度融合，新质生产力 ...

Group 1 - The core focus of Huace Testing is on performance verification of aerospace materials and reliability testing of core components, primarily serving private aerospace enterprises [10][11] - The company plans to enhance its service capabilities in the aviation sector, expanding into lifecycle testing services for new aircraft types such as drones and flying cars [10][11] - Huace Testing is strategically positioning itself in emerging sectors like AI, humanoid robots, silver economy, and low-altitude economy, with a focus on electric vehicle testing and semiconductor chip testing [10][11] Group 2 - Huace Testing has successfully integrated its acquisitions, with a focus on maintaining business continuity through complementary advantages, ensuring smooth collaboration between domestic and international teams [11] - The company has completed the acquisition of Safety SA, Emicert, Openview, and MIDAC laboratory, which are now officially consolidated into its financial statements [10][11] Group 3 - The average stock price of companies under institutional research increased by nearly 1% in the past week, with notable gains from companies like Huazhi Electromechanical, which saw a weekly increase of over 36% [14][15] - Huazhi Electromechanical has established a business partnership with Blue Arrow Aerospace in the commercial aerospace sector, while also focusing on potential applications in the aerospace and satellite fields [14][15] - The company has developed a "N+1+3" structure in its robotics business, indicating a diversified approach to core components and application scenarios [14][15] Group 4 - Companies like Aima Technology, Juxing Agriculture, LiuGong, and Xiangyu Medical have also attracted significant institutional interest, with over 50 institutions conducting research on them [13] - LiuGong reported balanced revenue distribution across nine major overseas regions, with a strong outlook for growth in the global construction machinery market by 2026 [13] - Xiangyu Medical is exploring both invasive and non-invasive brain-machine interface technologies, aiming for a unified approach to treatment effectiveness [14][15]